XML 98 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and other intangible assets (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 01, 2023
Apr. 18, 2022
Sep. 30, 2023
Apr. 30, 2023
Jun. 30, 2023
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2017
Goodwill and other intangible assets                    
In-process research and development impairment                 $ 3,500,000  
Goodwill impairment loss               $ 3,873,079    
Intangible asset impairment loss               2,277,921    
Increase in deferred tax liability               (571,120) (3,288,937)  
IPRD                    
Goodwill and other intangible assets                    
Balance of finite-lived intangible assets             $ 3,500,000 0 0  
Intangible asset impairment loss                 3,500,000  
Pelican Therapeutics, Inc.                    
Goodwill and other intangible assets                    
Goodwill acquired                   $ 2,200,000
Goodwill impairment loss             1,500,000      
Pelican Therapeutics, Inc. | IPRD                    
Goodwill and other intangible assets                    
Finite-lived intangible assets acquired                   $ 5,900,000
Carrying value written down             5,900,000      
Intangible assets fair value             3,500,000      
In-process research and development impairment           $ 3,500,000 $ 2,400,000      
Elusys Therapeutics                    
Goodwill and other intangible assets                    
Goodwill acquired   $ 3,300,000             5,067,748  
Finite-lived intangible assets acquired   $ 9,700,000                
In-process research and development impairment $ 0               0  
Goodwill impairment loss     $ 3,900,000         3,873,079    
Remaining amortization period   80 months                
Goodwill   $ 3,873,080     $ 3,900,000       3,301,959  
Acquisition fair value adjustments         $ 600,000     571,120 1,765,789  
Intangible asset impairment loss     2,300,000              
Amount of impairment charges     $ 0              
Increase in goodwill       $ 600,000            
Increase in other assets       1,000,000.0            
Increase in liability for uncertain tax positions       1,000,000.0            
Increase in deferred tax liability       $ 600,000            
Elusys Therapeutics | Intangible Assets                    
Goodwill and other intangible assets                    
Finite-lived intangible assets acquired                 11,200,000  
Balance of finite-lived intangible assets                 $ 8,669,375  
Intangible asset impairment loss               $ 2,277,921